MariTide: What Do We Know About Amgen’s Treatment?

Making sense of the MariTide research

MariTide is being studied as a weight-loss injection that could be given less often than today’s weekly treatments. The early results are interesting, but it is still in development. Here is what has been tested and what remains uncertain.

MariTide research guide: a woman seated in a community garden, with The Care Pharmacy branding

What is MariTide?

MariTide is an experimental treatment being developed by Amgen for weight management and related conditions. Its scientific name is maridebart cafraglutide. Older reports may call it AMG 133. All three names refer to the same treatment.

It combines a peptide with an antibody, a type of protein. This design is intended to keep it working in the body for longer. Researchers are testing injections given monthly and, in some studies, less often.

MariTide acts on two hormone pathways. It activates the GLP-1 receptor and blocks the GIP receptor. That second action is different from tirzepatide, which activates both GIP and GLP-1 receptors. Two treatments involving the same hormone names can therefore work differently.

MariTide is still being studied, and The Care Pharmacy does not supply it. Researchers need to establish whether a longer gap between injections makes treatment easier to manage and whether people can keep taking it safely outside a closely monitored clinical trial.

What did the MariTide phase 2 trial show?

The phase 2 study published in the New England Journal of Medicine enrolled 592 adults. It included a group with obesity without type 2 diabetes and a separate group with obesity and type 2 diabetes.

At 52 weeks, average weight loss in the group without diabetes ranged from 12.3% to 16.2% across the MariTide treatment groups, compared with 2.5% with placebo. Those estimates accounted for participants whether or not they continued their assigned treatment.

You may also have seen a figure of around 20%. It comes from a different analysis estimating the effect if people remained on treatment. Both can be useful, but they answer different questions. Leaving out how the figure was calculated can make a headline sound more certain than the study allows.

These were group averages under trial conditions. They cannot predict your own result. The study also did not directly compare MariTide with Mounjaro or Wegovy, so it cannot establish that one is the better choice.

Does monthly treatment mean fewer side effects?

Not necessarily. How often a medicine is taken and how well it is tolerated are different questions. A medicine can be given less often and still cause side effects.

Amgen’s report of the phase 2 results describes gastrointestinal symptoms, including nausea and vomiting. Symptoms were more common early in treatment, and the way treatment was started affected tolerability.

The practical question is whether people can continue treatment comfortably enough to benefit from it. To judge that, clinicians look at how many people report symptoms, how severe they are and how many stop. Describing a treatment as convenient does not answer those questions.

A longer-lasting medicine also needs careful safety assessment. Research teams need to understand its effects over time, including after an injection has been given. The trial schedule should not be copied with a product bought online.

If you are having problems with a prescribed weekly injection, speak to your prescriber. Do not stretch the interval between doses or change treatment yourself because a different medicine is being studied monthly.

What are the MARITIME studies testing?

MARITIME is the name of the larger phase 3 research programme. In its November 2026 development update, Amgen lists ongoing studies of weight management, including separate studies for people with and without type 2 diabetes.

Other studies examine outcomes such as cardiovascular disease, heart failure and obstructive sleep apnoea. There is also research into maintaining weight loss and switching from existing weekly medicines. Each study has its own design and eligibility requirements.

The existence of a study does not establish its result. For example, a trial looking at heart problems cannot be described as proof that MariTide prevents them before the relevant findings have been reported and assessed.

Likewise, a switching study does not provide instructions for patients to switch now. It tests a planned change under research supervision. Your current treatment should continue to be reviewed on its own merits with your prescriber.

When could MariTide be available in the UK?

There is no confirmed routine UK supply date to give here. MariTide is still in development. Successful trials would need to be followed by a regulatory assessment before it could become an authorised medicine.

A company discussing future production or further trials is not announcing UK approval. Overseas news also needs to be read carefully: a trial starting in one country does not make the treatment available through UK pharmacies.

We cannot provide an approved dose, prescription price or NHS eligibility criteria for MariTide. Guessing those details would not help you plan care. If its status changes, information about the authorised use and actual supply would be needed.

Online sellers may use a familiar research name without supplying the medicine tested in the trials. Do not take a name, laboratory certificate or social media recommendation as evidence that a product is suitable to inject.

What matters beyond the weight-loss percentage?

It is understandable to be interested in a treatment that might mean fewer injections. For some people, managing weekly treatment around work, travel or other medicines is difficult. But convenience is only one part of a treatment decision.

  • Can the person tolerate the medicine and keep taking it?
  • Does the evidence include people with their health conditions?
  • What follow-up and support will they need?
  • How will ongoing treatment be paid for?

There also needs to be a plan for reviewing progress. Weight is one measure, but symptoms, nutrition, other health conditions and side effects matter too. A treatment that produces a large average change in a trial will not necessarily be the right fit for everyone.

These questions apply to medicines available today as well as those in development. A consultation gives you a chance to discuss what would make treatment workable for you, rather than choose from a list of headline percentages.

Considering weight-loss treatment now

Licensed weight-loss medicines are already available on prescription, alongside support with eating and activity. The NHS information on overweight and obesity explains the range of care, including when specialist services may be appropriate.

For private care, start with an assessment of your health and current medicines. Be clear about previous weight-loss treatment, why you stopped and any side effects. If you have been receiving care elsewhere, tell the prescriber when you last used your medicine.

You can also ask practical questions before starting: how follow-up works, who to contact if you feel unwell and what the ongoing cost is likely to include. The right time to discuss these details is before treatment, rather than after ordering a medicine.

Common questions about MariTide

Is maridebart cafraglutide a separate medicine?

No. It is the scientific name for the treatment known as MariTide. AMG 133 is its earlier development code.

Is it the same as Mounjaro?

No. The ingredients and the way they act on hormone receptors differ. MariTide is investigational; Mounjaro is a licensed prescription medicine for specified uses.

Will everyone only need an injection every three months?

That has not been established. Different intervals are being researched, including maintenance schedules. They should not be described as an approved routine for all patients.

Should I wait for it before getting help?

You can discuss weight-management support now. A future treatment’s development timetable should not prevent you asking about appropriate care for your current health.

Find out whether weight-loss treatment is suitable for you

If you would like help choosing a weight-loss treatment, complete our online consultation. Our prescriber will review your health and current medicines to assess whether treatment is suitable.

Start consultation

This guide gives general information. Ask a qualified healthcare professional about your own treatment.

Prescription medicines require a clinical assessment. The clinician may recommend a different treatment or an in-person appointment.

Clinical reviewer

Mohammed Ismail Lakhi, MPharm, is the Superintendent Pharmacist at The Care Pharmacy. He leads clinical governance and is registered with the General Pharmaceutical Council, registration number 2072815.

Medically reviewed by

Mohammed Lakhi

Superintendent Pharmacist

Muhammad Lahki
Mohammed Ismail Lakhi

Ecnoglutide: What Can UK Readers Learn From the Trials?

Ecnoglutide is another name appearing in weight-management research. This guide explains its own trial evidence and the limits of overseas approval.

Read More

Mazdutide: What Does Approval in China Mean for the UK?

A medicine’s approval in one country does not settle its status elsewhere. Here is how to read the mazdutide evidence without confusing the two.

Read More

Survodutide: What Do Its Weight-Loss Trials Tell Us?

Survodutide is a separate treatment under development. Read what its obesity research has measured and why trial results need context.

Read More

Petrelintide: What Is This Amylin Treatment?

Petrelintide is an investigational amylin treatment. Read what the studies have measured and why a trial result is different from a treatment recommendation.

Read More

Eloralintide: What Do the Weight-Loss Trials Show?

Eloralintide is being studied as a weight-management treatment. This guide explains the trial findings and the questions they have yet to answer.

Read More

Orforglipron: Eli Lilly’s New Oral GLP-1 Weight Loss Treatment

A new clinical analysis suggests that orforglipron, Eli Lilly’s first GLP-1 weight-loss pill, may become a strong alternative to weekly injections like Wegovy and Mounjaro. The findings come from the latest GLP-1 study 2025, where researchers reported meaningful reductions in body weight, improved blood sugar control, and benefits for adults living with type 2 diabetes […]

Read More
icon
UK-Prescribing Pharmacists
icon
No GP Appointments Needed
icon
Fast & Discreet Delivery